| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY WHSSC POLICY PUBLISHED JANUARY 2022. Refer to PP228: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 and older) for full recommendations, including any specific restrictions on the use of the technology. |
|
Medicine details |
|
| Medicine name | canakinumab (Ilaris®) |
| Formulation | Powder for solution for injection |
| Reference number | 2093 |
| Indication | Treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS) in adults, adolescents and children aged 2 years and older; treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) in adults, adolescents and children aged 2 years and older; treatment of Familial Mediterranean Fever (FMF) in adults, adolescents and children aged 2 years and older. Ilaris should be given in combination with colchicine, if appropriate |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | Non-submission |
| Status | Superseded |
| Date of issue | 25/05/2017 |
| Further information |
|